NAGE
Niagen Bioscience Inc
$3.21
+0.06
(+1.90%)
Mkt Cap
255.66M
Volume
370,320
52W Range
2.87-10.52
Sector
Healthcare
Beta
2.09
EPS (TTM)
0.19 USD
P/E Ratio
16.53
Revenue (TTM)
129.08M USD
Rev Growth (5Y)
+16.9%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$5.20
Undervalued
moderate signal
38.3% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
A platform business that compounds free cash flow — graded A–F vs. similar companies.
Company Description
Niagen Bioscience Inc operates as a biotechnology enterprise with a core focus on promoting healthy aging. This company is also renowned for its pioneering research into nicotinamide adenine dinucleotide.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 129.42M | 99.60M | 83.57M | 72.05M | 67.45M | 59.26M | 46.29M | 31.56M | 21.20M | 21.66M | 17.88M | 15.31M |
| Net Income | 17.38M | 8.55M | (4.94M) | (16.54M) | (27.13M) | (19.93M) | (32.15M) | (33.32M) | (11.38M) | (2.93M) | (2.77M) | (5.39M) |
| EPS | 0.22 | 0.11 | -0.07 | -0.24 | -0.40 | -0.33 | -0.56 | -0.61 | -0.26 | -0.08 | -0.08 | -0.15 |
| Free Cash Flow | 13.14M | 11.95M | 6.97M | (15.43M) | (24.57M) | (10.74M) | (21.19M) | (22.36M) | (11.15M) | (4.66M) | (2.76M) | (2.83M) |
| FCF / Share | 0.17 | 0.15 | 0.10 | -0.22 | -0.37 | -0.18 | -0.37 | -0.41 | -0.25 | -0.12 | -0.08 | -0.08 |
| Operating CF | 13.44M | 12.11M | 7.12M | (15.10M) | (24.16M) | (10.60M) | (20.44M) | (20.91M) | (9.80M) | (2.94M) | (2.11M) | (2.58M) |
| Total Assets | 106.41M | 68.28M | 54.96M | 54.06M | 57.84M | 38.36M | 40.25M | 42.23M | 62.72M | 19.75M | 18.75M | 11.52M |
| Total Debt | 2.82M | 2.65M | 3.28M | 4.26M | 4.70M | 1.64M | 1.72M | 310,000 | 506,000 | 599,050 | 5.54M | 2.77M |
| Cash & Equiv | 64.79M | 44.51M | 27.17M | 20.29M | 28.02M | 16.50M | 18.61M | 22.42M | 45.39M | 1.64M | 5.55M | 3.96M |
| Book Value | 76.53M | 46.09M | 28.46M | 28.67M | 31.73M | 16.42M | 20.45M | 27.18M | 53.83M | 9.97M | 5.27M | 4.00M |
| Return on Equity | 0.23 | 0.19 | -0.17 | -0.58 | -0.86 | -1.21 | -1.57 | -1.23 | -0.21 | -0.29 | -0.53 | -1.35 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 29.79M | 31.47M | 33.84M | 33.99M | 31.12M | 30.48M | 29.12M | 25.58M | 22.74M | 22.15M | 21.20M | 19.50M |
| Net Income | 963,000 | 6.32M | 4.13M | 4.58M | 3.61M | 5.06M | 7.18M | 1.88M | (15,000) | (492,000) | 114,000 | (959,000) |
| EPS | 0.01 | 0.08 | 0.05 | 0.05 | 0.05 | 0.07 | 0.09 | 0.02 | -0.00 | -0.01 | 0.00 | -0.01 |
| Free Cash Flow | 2.68M | (1.25M) | 578,000 | 3.67M | 1.11M | 7.85M | 8.51M | 3.45M | (276,000) | 254,000 | 628,000 | 370,000 |
| FCF / Share | 0.03 | -0.02 | 0.01 | 0.04 | 0.01 | 0.10 | 0.11 | 0.04 | -0.00 | 0.00 | 0.01 | 0.00 |
| Operating CF | 2.77M | (1.19M) | 679,000 | 3.69M | 1.25M | 7.88M | 8.58M | 3.50M | (264,000) | 295,000 | 649,000 | 396,000 |
| Total Assets | 106.59M | 114.33M | 106.41M | 98.14M | 91.53M | 81.34M | 68.28M | 56.52M | 54.03M | 54.08M | 54.96M | 53.48M |
| Total Debt | 2.33M | 2.58M | 2.82M | 3.06M | 3.29M | 3.52M | 2.65M | 2.90M | 3.12M | 3.23M | 3.28M | 3.79M |
| Cash & Equiv | 66.74M | 66.55M | 64.79M | 64.14M | 60.32M | 55.46M | 44.51M | 32.25M | 27.73M | 27.41M | 27.17M | 26.62M |
| Book Value | 82.53M | 82.33M | 76.53M | 70.68M | 64.19M | 55.34M | 46.09M | 34.37M | 30.72M | 28.95M | 28.46M | 27.31M |
| Return on Equity | 0.01 | 0.08 | 0.05 | 0.06 | 0.06 | 0.09 | 0.16 | 0.05 | -0.00 | -0.02 | 0.00 | -0.04 |
NAGE News
Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam's Club
Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam's Club
Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference
Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence
Niagen Bioscience, Inc. (NAGE) Q2 2026 Earnings Call Transcript
Niagen Bioscience (NAGE) Meets Q2 Earnings Estimates
Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biologic
Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging